Ernest Boyd
Human Genome Sciences
4 Papers
Ernest Boyd is an academic researcher from Human Genome Sciences. The author has contributed to research in topics: Caspase 3 & Internal medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator
Thi Sau Migone,Jun Zhang,Xia Luo,Li Zhuang,Cecil Chen,Bugen Hu,June S. Hong,James W. Perry,Su Fang Chen,Joe X. H. Zhou,Yun Hee Cho,Stephen Ullrich,Palanisamy Kanakaraj,Jeffrey Carrell,Ernest Boyd,Henrik S. Olsen,Gang Hu,Laurie Pukac,Ding Liu,Jian Ni,Sunghee Kim,Reiner L. Gentz,Ping Feng,Paul A. Moore,Steve Ruben,Ping Wei +25 more
TL;DR: The data suggest that interaction of TL1A with DR3 promotes T cell expansion during an immune response, whereas TR6 has an opposing effect.
671
Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.
Wendy Halpern,Todd A. Riccobene,Heidi Agostini,Kevin P. Baker,David Stolow,Mili Gu,Jonathan Hirsch,Angela Mahoney,Jeffrey Carrell,Ernest Boyd,Krzysztof J. Grzegorzewski +10 more
TL;DR: The sustained activity of Albugranin in mice and monkeys demonstrated in these studies suggests that this agent could be given less frequently than Filgrastim to achieve similar therapeutic effects in patients.
116
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
Palanisamy Kanakaraj,Bridget A. Puffer,Xiao-Tao Yao,Spandana Kankanala,Ernest Boyd,Rutul R. Shah,Geping Wang,Dimki R. Patel,Rajesh Krishnamurthy,Shashi Kaithamana,Rodger Smith,David W. Lafleur,Carlos F. Barbas,David M. Hilbert,Peter Kiener,Viktor Roschke +15 more
TL;DR: In a TNF transgenic mouse model of arthritis, the bispecific anti-TNF-Ang2 molecules showed a dose-dependent reduction in both clinical symptoms and histological scores that were significantly better than that achieved by adalimumab alone.
69
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
Laurie Pukac,Palanisamy Kanakaraj,Robin Humphreys,R Alderson,M Bloom,Cynthia Sung,Todd A. Riccobene,R. Johnson,Michele Fiscella,Angela Mahoney,Jeff Carrell,Ernest Boyd,X T Yao,Linyi Zhang,L Zhong,A. Von Kerczek,Lindsey Shepard,T Vaughan,B Edwards,C Dobson,Theodora W. Salcedo,Vivian R. Albert +21 more
TL;DR: In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models, and combined with chemotherapeutic agents resulted in an enhanced antitumour efficacy compared to either agent alone.